NEW DELHI, Dec 14 (Reuters) – India is struggling to export its surplus of COVID-19 vaccines as logistical hurdles delay their use in many countries despite low levels of inoculation, vaccine producer the Serum Institute of India (SII) and a government official said on Tuesday. “Certain countries have only vaccinated to the tune of 10 or 15 percent of the population, they really need to go to 60-70%. “India is in a position to offer vaccines, but is there traction (for it)?” he asked. India’s vaccine demand was only about 252 million doses in the past month, against a domestic production capacity of more than 345 million a month of its three main approved shots alone. The SII’s monthly output of the AstraZeneca vaccine, which it brands Covishield, has nearly quadrupled since April to 250 million doses.
